KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the granting of inducement options to six newly-hired employees. These options, totaling 31,000 shares of KalVista common stock, were granted on October 1, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.39 per share, matching the closing price of KalVista common stock on the grant date.
The vesting schedule for these options includes 25% vesting on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years. Each option has a 10-year term and is subject to KalVista's Inducement Equity Incentive Plan and a stock option agreement.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) ha annunciato l'assegnazione di opzioni di indennizzo a sei nuovi assunti. Queste opzioni, per un totale di 31.000 azioni di azioni ordinarie di KalVista, sono state concesse il 1 ottobre 2024, in conformità con la Nasdaq Listing Rule 5635(c)(4). Le opzioni hanno un prezzo di esercizio di $11,39 per azione, corrispondente al prezzo di chiusura delle azioni ordinarie di KalVista nella data di concessione.
Il piano di maturazione per queste opzioni prevede il 25% di maturazione al primo anniversario della data di inizio della maturazione, con il restante 75% che matura in rate mensili uguali nei successivi tre anni. Ogni opzione ha un termine di 10 anni ed è soggetta al Piano di Incentivi in Azioni di Indennizzo di KalVista e a un contratto di opzione su azioni.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) ha anunciado la concesión de opciones de inducción a seis nuevos empleados. Estas opciones, que suman 31,000 acciones de acciones ordinarias de KalVista, fueron otorgadas el 1 de octubre de 2024, de acuerdo con la Regla 5635(c)(4) de Nasdaq. Las opciones tienen un precio de ejercicio de $11.39 por acción, que coincide con el precio de cierre de las acciones ordinarias de KalVista en la fecha de concesión.
El calendario de adquisición para estas opciones incluye el 25% de adquisición en el primer aniversario de la fecha de inicio de la adquisición, con el 75% restante adquiriéndose en cuotas mensuales iguales durante los próximos tres años. Cada opción tiene un plazo de 10 años y está sujeta al Plan de Incentivo de Capital de Inducción de KalVista y a un acuerdo de opción sobre acciones.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)는 새로 고용된 직원 6명에게 유도 옵션을 부여했다고 발표했습니다. 이 옵션은 총 31,000주의 KalVista 일반 주식으로, 2024년 10월 1일에 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 진행되었습니다. 옵션의 행사가격은 주당 $11.39로, 부여일의 KalVista 일반 주식 종가와 일치합니다.
이 옵션의 가속일정은 가속 시작일의 1주년 기념일에 25%가 가속된다는 조건을 포함하며, 나머지 75%는 다음 3년 동안 매월 균등 분할로 가속된다는 조건이 포함되어 있습니다. 각 옵션에는 10년의 기간이 있으며, KalVista의 유도 주식 인센티브 계획 및 주식 옵션 계약의 적용을 받습니다.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) a annoncé l'octroi d'options d'incitation à six nouveaux employés. Ces options, totalisant 31 000 actions de l'action ordinaire de KalVista, ont été accordées le 1er octobre 2024, conformément à la règle d'inscription Nasdaq 5635(c)(4). Les options ont un prix d'exercice de 11,39 $ par action, correspondant au prix de clôture de l'action ordinaire de KalVista à la date d'octroi.
Le calendrier d'acquisition pour ces options inclut un acquisition de 25 % à l'anniversaire d'un an de la date de début de l'acquisition, le reste de 75 % s'acquérant en versements mensuels égaux sur les trois années suivantes. Chaque option a une durée de 10 ans et est soumise au Plan d'incitation en actions de KalVista ainsi qu'à un contrat d'option d'achat d'actions.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) hat die Gewährung von Induktionsoptionen an sechs neu eingestellte Mitarbeiter bekannt gegeben. Diese Optionen, insgesamt 31.000 Aktien von KalVista-Stammaktien, wurden am 1. Oktober 2024 gewährt, gemäß der Nasdaq-Listing-Regel 5635(c)(4). Die Optionen haben einen Ausübungspreis von 11,39 $ pro Aktie, was dem Schlusskurs der KalVista-Stammaktien am Tag der Gewährung entspricht.
Der Vesting-Plan für diese Optionen sieht vor, dass 25% nach einem Jahr ab dem Vesting-Startdatum anfallen, während die restlichen 75% in gleichmäßigen monatlichen Raten über die folgenden drei Jahre fallen. Jede Option hat eine Laufzeit von 10 Jahren und unterliegt dem Induktionsaktienanreizplan von KalVista sowie einem Aktienoptionsvertrag.
- Granting of stock options may help attract and retain talented employees
- The company is expanding its workforce with six new hires
- None.
The options have an exercise price of
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company that seeks to develop and deliver oral medicines for diseases with significant unmet need. The Company is focused on understanding the needs of patients and the limitations of current therapies to design treatments that empower people to better manage their disease and improve their lives. In August 2024, the Company announced its NDA for sebetralstat for hereditary angioedema (HAE) was accepted by the
For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241002290608/en/
KalVista Pharmaceuticals, Inc.
Media:
Jenn Snyder
Vice President, Corporate Affairs
(857) 356-0479
jennifer.snyder@kalvista.com
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
How many shares of KALV stock were granted as inducement options on October 1, 2024?
What is the exercise price for the KALV inducement options granted on October 1, 2024?
What is the vesting schedule for the KALV inducement options granted on October 1, 2024?
What is the term length of the KALV inducement options granted on October 1, 2024?
